Development and Validation of a High-Performance Liquid Chromatography With Ultraviolet Detection Method to Facilitate Therapeutic Monitoring of Teicoplanin Using Dried Blood Spots.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
21
12
2023
accepted:
13
02
2024
medline:
25
6
2024
pubmed:
25
6
2024
entrez:
25
6
2024
Statut:
aheadofprint
Résumé
In neonatal and pediatric intensive care units, Gram-positive infections are a significant cause of morbidity and mortality. The increase in infections caused by methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphylococci have led to the increased use of glycopeptides, which treat invasive infections caused by Gram-positive organisms, particularly those resistant to beta-lactam antibiotics. Teicoplanin has bacteriostatic activity against Gram-positive bacteria, but its pharmacokinetics in children is highly variable, with most children failing to reach target levels at the recommended dose. This study aimed to develop a cost-effective method for determining concentrations using dried blood spot (DBS). A method to determine the concentrations of teicoplanin in 20 µL blood or plasma using the Whatman 903 Protein Saver filter was evaluated. High-performance liquid chromatography with ultraviolet detection high-performance liquid chromatography with ultraviolet/vis was used, with internal standard ketoconazole. In addition, a method to quantify teicoplanin using 50 µL of liquid plasma was established to compare the results with the values obtained by DBS and dried plasma methods. The method was successfully developed and validated for 20 µL DBS. Furthermore, 50 µL of plasma was used to quantify teicoplanin with a lower limit of quantification of 10 mg/L. Precision and accuracy ranged from 2.3% to 10.7% and 95%-114.2%, respectively. A consistent factor (1.15) was used to calculate teicoplanin plasma concentrations from whole blood, indicating the reliability of the DBS method for therapeutic drug monitoring of teicoplanin. A simple, reliable, and cost-effective method using high-performance liquid chromatography with ultraviolet/vis was established to determine pediatric teicoplanin concentrations in both small plasma sample volumes and whole blood using DBS, and an accurate correlation factor for estimating teicoplanin plasma concentrations from DBS was identified. This method is suitable for the use in pediatrics.
Sections du résumé
BACKGROUND
BACKGROUND
In neonatal and pediatric intensive care units, Gram-positive infections are a significant cause of morbidity and mortality. The increase in infections caused by methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphylococci have led to the increased use of glycopeptides, which treat invasive infections caused by Gram-positive organisms, particularly those resistant to beta-lactam antibiotics. Teicoplanin has bacteriostatic activity against Gram-positive bacteria, but its pharmacokinetics in children is highly variable, with most children failing to reach target levels at the recommended dose. This study aimed to develop a cost-effective method for determining concentrations using dried blood spot (DBS).
METHODS
METHODS
A method to determine the concentrations of teicoplanin in 20 µL blood or plasma using the Whatman 903 Protein Saver filter was evaluated. High-performance liquid chromatography with ultraviolet detection high-performance liquid chromatography with ultraviolet/vis was used, with internal standard ketoconazole. In addition, a method to quantify teicoplanin using 50 µL of liquid plasma was established to compare the results with the values obtained by DBS and dried plasma methods.
RESULTS
RESULTS
The method was successfully developed and validated for 20 µL DBS. Furthermore, 50 µL of plasma was used to quantify teicoplanin with a lower limit of quantification of 10 mg/L. Precision and accuracy ranged from 2.3% to 10.7% and 95%-114.2%, respectively. A consistent factor (1.15) was used to calculate teicoplanin plasma concentrations from whole blood, indicating the reliability of the DBS method for therapeutic drug monitoring of teicoplanin.
CONCLUSIONS
CONCLUSIONS
A simple, reliable, and cost-effective method using high-performance liquid chromatography with ultraviolet/vis was established to determine pediatric teicoplanin concentrations in both small plasma sample volumes and whole blood using DBS, and an accurate correlation factor for estimating teicoplanin plasma concentrations from DBS was identified. This method is suitable for the use in pediatrics.
Identifiants
pubmed: 38917389
doi: 10.1097/FTD.0000000000001202
pii: 00007691-990000000-00241
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ramos-Martín V, Paulus S, Siner S, et al. Population pharmacokinetics of teicoplanin in children. Antimicrob Agents Chemother. 2014;58:6920–6927.
Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000;39:167–183.
Choi J-S, Yoon SH, Park HJ, et al. Optimal use and need for therapeutic drug monitoring of teicoplanin in children: a systematic review. J Korean Med Sci. 2023;38:e62.
Wang X-X, Jin P-F, Li P-M, et al. Interlaboratory analysis of teicoplanin plasma concentration assays among Chinese laboratories. J Clin Pharm Ther. 2020;45:983–990.
Pea F. Teicoplanin and therapeutic drug monitoring: an update for optimal use in different patient populations. J Infect Chemother. 2020;26:900–907.
Yamada T, Kubota T, Nakamura M, et al. Evaluation of teicoplanin concentrations and safety analysis in neonates. Int J Antimicrob Agents. 2014;44:458–462.
Yamada T, Kubota T, Yonezawa M, et al. Evaluation of teicoplanin trough values after the recommended loading dose in children with associated safety analysis. Pediatr Infect Dis J. 2017;36:398–400.
Loane G, Gwee A. Teicoplanin therapeutic drug monitoring and treatment outcomes in children with gram-positive infections. J Pediatr Infect Dis Soc. 2021;10:682–685.
Roberts JA, Stove V, De Waele J, et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. Int J Antimicrob Agents. 2014;43:423–430.
Marrubini G, Tengattini S, Colombo R, et al. A new MS compatible HPLC-UV method for Teicoplanin drug substance and related impurities, part 1: development and validation studies. J Pharm Biomed Anal. 2019;162:185–191.
Tengattini S, Corana F, Bianchi D, et al. Application of an HPLC-MS/MS method for Teicoplanin drug substance and related impurities, part 2: identity assignment of related impurities. J Pharm Biomed Anal. 2019;168:38–43.
Levy J, Truong BL, Goignau H, et al. High pressure liquid chromatographic quantitation of teicoplanin in human serum. J.Antimicrob Chemother. 1987;19:533–539.
Hanada K, Kobayashi A, Okamori Y, et al. Improved quantitative determination of total and unbound concentrations of six teicoplanin components in human plasma by high performance liquid chromatography. Biol Pharm Bull. 2005;28:2023–2025.
Passoni MH, Salgado HRN. Development and validation of a new and rapid HPLC for determination of lyophilized teicoplanin. Anal Methods. 2012;4:1560–1564.
Shen J, Jiao Z, Zhou Y, et al. Quantification of teicoplanin in human plasma by liquid chromatography with ultraviolet detection. Chroma. 2006;65:9–12.
McCann SJ, White LO, Keevil B. Assay of teicoplanin in serum: comparison of high-performance liquid chromatography and fluorescence polarization immunoassay. J Antimicrob Chemother. 2002;50:107–110.
Urakami T, Maiguma T, Kaji H, et al. Analysis using fluorescence polarization immunoassay for unbound teicoplanin concentration in serum. J Clin Pharm Ther. 2008;33:357–363.
U.S. Department of Health and Human Services—Food and Drug Administration (FDA). Bioanalytical Method Validation Guidance for Industry; 2018. Available at: https://www.fda.gov/media/70858/download. Accessed September 21, 2021.
European Medicines Agency. Guideline on Bioanalytical Method Validation; 2015. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-methodvalidation_en.pdf. Accessed September 11, 2021.
Jopling J, Henry E, Wiedmeier SE, et al. Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data from a multihospital health care system. Pediatrics. 2009;123:e333–e337.
Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis. 2010;2:1385–1395.
Ye Z, Gao H. Evaluation of sample extraction methods for minimizing hematocrit effect on whole blood analysis with volumetric absorptive microsampling. Bioanalysis. 2017;9:349–357.
Martens-Lobenhoffer J, Monastyrski D, Tröger U, et al. Stability of meropenem in plasma versus dried blood spots (DBS). J Pharm Biomed Anal. 2019;170:279–284.
Lee J, Chung E-K, Kang S-W, et al. Quantification of teicoplanin using the HPLC-UV method for clinical applications in critically ill patients in korea. Pharmaceutics. 2021;13:572.